Literature DB >> 31774947

Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs.

Giovanni A Fava1,2, Fiammetta Cosci3.   

Abstract

Withdrawal symptoms commonly occur during tapering and/or after discontinuation of antidepressant drugs, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Withdrawal symptomatology does not necessarily subside within a few weeks and may be associated with other manifestations of behavioral toxicity (loss of treatment efficacy, refractoriness, switch into mania/hypomania, or paradoxical reactions). The oppositional model of tolerance provides a pathophysiologic basis for understanding and managing withdrawal syndromes. Reintroducing the antidepressant that was initially used or switching from one antidepressant to another to suppress symptomatology, as suggested by current guidelines, may actually aggravate the state of behavioral toxicity and be detrimental in the long run. Alternative strategies that do not encompass continuation of antidepressant treatment are required, but there is currently lack of adequate research for guiding the clinical approach. Some tentative suggestions are provided. © Copyright 2019 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31774947     DOI: 10.4088/JCP.19com12794

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  [Pharmacotherapy of anxiety disorders-Guideline-conform treatment and new developments].

Authors:  P Zwanzger; N Singewald; B Bandelow
Journal:  Nervenarzt       Date:  2021-01-27       Impact factor: 1.214

2.  Effect of Electroacupuncture on Insomnia in Patients With Depression: A Randomized Clinical Trial.

Authors:  Xuan Yin; Wei Li; Tingting Liang; Bing Lu; Hongyu Yue; Shanshan Li; Victor W Zhong; Wei Zhang; Xia Li; Shuang Zhou; Yiqun Mi; Huangan Wu; Shifen Xu
Journal:  JAMA Netw Open       Date:  2022-07-01

3.  Can oral formulation increase the risk of lormetazepam abuse?

Authors:  Enrico Costa; Enrico Sterzi; Federico Tedeschi; Rebecca Casari; Paola Marini; Fabio Lugoboni
Journal:  Intern Emerg Med       Date:  2020-10-23       Impact factor: 3.397

Review 4.  How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding.

Authors:  Michael P Hengartner
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-08

5.  Recurrent Episodes of Paraphilic Behavior Possibly Associated With Olanzapine and Aripiprazole Treatment in a Patient With Schizophrenia.

Authors:  Maria-Ioanna Stefanou; Debora Vittore; Ines Wolz; Stefan Klingberg; Dirk Wildgruber
Journal:  Front Psychiatry       Date:  2020-04-20       Impact factor: 4.157

6.  Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum.

Authors:  Michael P Hengartner; Lukas Schulthess; Anders Sorensen; Adele Framer
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-24

7.  Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?

Authors:  Fiammetta Cosci; Giovanni A Fava
Journal:  Biomed Hub       Date:  2021-11-01

8.  To continue or discontinue antidepressants in anxiety disorders? A dilemma for patients and clinicians.

Authors:  Anna Muntingh; Neeltje Batelaan; Willemijn Scholten; Anton J van Balkom
Journal:  J Psychiatry Neurosci       Date:  2021-06-02       Impact factor: 6.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.